Semperit Group Achieved Double-Digit Growth Rates
Revenue increased by 18.9% to € 820.0m. The Austrian producer of synthetic products recorded an increase in earnings after tax by 19.2% to € 54.1m.
Semperit Group with its medical sector (Sempermed) and industrial sector (Semperflex, Sempertrans and Semperform) increased year on year revenue in 2011 by 18.9% to € 820.0m. Sales growth is primarily derived from higher prices as a result of increasing cost of raw materials but also increased volumes in all sectors. The breakdown by sector shows an increase in revenues in Sempermed of 17.4% to € 371.5m, in Semperflex by 28.5% to € 186.9m, in Sempertrans by 24.5% to € 147.0m and in Semperform by 4.7% to € 114.6m.
Earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 0.5% to € 112.8m in comparison with the previous year. The operating result (EBIT) increased by 0.9% to € 83.1m. Net income increased by 19.2% from € 45.4m to € 54.1m. Earnings per share increased in line with net income to a value of € 2.63.
Semperit Group´s financial independence is highlighted by its further increase in the equity ratio to 60.4% as of Dec. 31, 2011. Based on these results, the board will propose a dividend payment of € 0.80 per share at the Annual General Meeting. This proposal reflects the balance between an unaltered attractive shareholder return and a stronger growth orientation while maintaining a solid capital structure.
For 2012, Semperit Group foresees further moderate growth. Given the limited strategic visibility, primarily due to the continued volatile raw material markets and the macroeconomic conditions, an informed outlook regarding revenue and profit trends for 2012 is difficult at the current time. Semperit Group continues to follow its medium term target. On average, in the years up to and including 2015, double digit sales growth should be achieved while maintaining current profitability levels.